Key result
Analysis of 19 ACTA1 myopathy mutants revealed a range of molecular defects, including failure to fold, instability in the nucleotide-binding pocket, and inability to co-polymerize with wild-type actin.
Population
19 myopathy mutants of alpha-skeletal-muscle actin (ACTA1) studied in vitro and in NIH 3T3 fibroblasts
Comparison
Biochemical and cell biological analysis of… vs Wild-type actin
Design
Preclinical
Authors
Loading...
No immediate clinical implications for ACTA1 myopathy; leaves open mutation-specific therapeutic strategies.
ACTA1 myopathy mutations cause a diverse range of molecular defects in actin folding, protein interaction, and polymerization, paralleling the complexity of clinical phenotypes.
Costa et al. (2004) studied Congenital myopathies (n=19). ACTA1 mutations vs. Wild-type actin was evaluated on Actin folding, capacity to interact with actin-binding proteins, and polymerization. Analysis of 19 ACTA1 myopathy mutants revealed a range of molecular defects, including failure to fold, instability in the nucleotide-binding pocket, and inability to co-polymerize with wild-type actin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: